Compare PPSI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | EVAX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 42.7M |
| IPO Year | N/A | 2021 |
| Metric | PPSI | EVAX |
|---|---|---|
| Price | $4.74 | $4.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 240.3K | 65.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $31,751,000.00 | $7,650,000.00 |
| Revenue This Year | $26.84 | $128.77 |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | $1.64 | ★ N/A |
| Revenue Growth | 105.82 | ★ 132.17 |
| 52 Week Low | $2.25 | $1.20 |
| 52 Week High | $5.70 | $12.15 |
| Indicator | PPSI | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 33.45 |
| Support Level | $4.70 | $4.11 |
| Resistance Level | $5.24 | $4.85 |
| Average True Range (ATR) | 0.36 | 0.38 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 26.37 | 8.23 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.